Infosys down as investors fret over U.S. scrutiny
Reuters Market Eye - Shares in Infosys(INFY.NS), India's No. 2 software services company, fell over 3 percent on news that the company is under scrutiny from U.S. authorities for likely errors in employer eligibility documents of its staff.
"We believe that if the DHS concludes that there has been a systematic policy of misuse/violation of visas, there could be penalties or other strictures that could be imposed," Nomura said in a note, referring to the U.S. Department of Homeland Security.
(To read Infosys staff documents under U.S. scrutiny, click here)
The new development will add to concerns as the company will go on trial in August for alleged visa misuse and the current development may strengthen the case, Nomura said.
It also comes on the back of disappointing earnings on April 13, where the company disappointed investors with a weaker-than-expected revenue growth outlook for the current fiscal year.
Infosys, in a statement, said that any government action could materially and adversely affect its business and results of operations.
"We believe this is a negative development," Nomura added.
(Reporting by Manoj Dharra; Editing by Subhadip Sircar)
- Tweet this
- Share this
- Digg this
- Scots spurn independence in historic vote but demand new powers
- PM Modi says al Qaeda will fail in India - CNN
- India TV anchor's number is up after naming China's Xi 'Eleven'
- CORRECTED-UPDATE 2-SAP agrees to buy expense software maker Concur for $7.3 bln
- China not warlike, says Xi, as border standoff dominates India trip
India has capped the prices of 36 drugs, including those used to treat infections and diabetes, in its latest move to make essential medicines more affordable, a senior official of the country's drug pricing authority told Reuters on Friday. Full Article
Obama to nominate Indian-American Richard Verma as India ambassador - congressional source. Full Article
Top rice exporter India importing over 100,000 T on temporary supply squeeze. Full Article